Melanoma and solid tumour oncology
Erasca Inc. is focused on clinical research in unresectable and metastatic cutaneous melanoma, with particular attention to NRAS mutant disease. The sponsor’s active programme is centered on treatment options for patients with previously treated advanced melanoma.
- Cutaneous melanoma
- Metastatic cancer
- NRAS-mutant oncology
The research activity spans multiple collaborating sites across several countries, reflecting a broad international interest in advanced melanoma care.
Targeted therapy and MAPK pathway inhibition
The clinical portfolio includes interest in combination treatment strategies built around naporafenib and trametinib, with emphasis on pathway-directed treatment for NRAS-mutant melanoma.
- Kinase inhibition
- Signal transduction targeting
- Combination therapy
This area highlights a therapeutic focus on molecularly guided oncology approaches for patients whose disease has progressed after prior treatment.
Comparative oncology and standard-of-care treatment
Research interest also extends to comparing investigational treatment with established options used in advanced melanoma, including dacarbazine, temozolomide, and trametinib monotherapy.
- Physician’s choice therapy
- Advanced melanoma management
- Post-treatment disease control
The sponsor’s work is centered on treatment selection in the setting of previously treated metastatic disease.
Clinical operations in multinational oncology research
Erasca Inc., a pharmaceutical company based in San Diego, supports a clinical network involving numerous research sites across North America and other active countries. Its operational footprint is concentrated in oncology trials with international participation.
- Multicountry trial activity
- Site-based oncology research
- Recruiting clinical studies
The sponsor’s current research landscape is defined by a single active program in advanced melanoma.
